Compare

Collegium Pharmaceutical/$COLL

1D1W1M3M6MYTD1Y5YMAX

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Ticker
$COLL
Sector
Health
Primary listing
NASDAQ
Employees
423

COLL Metrics

BasicAdvanced
$768M
21.83
$1.13
0.73
-

What the Analysts think about COLL

Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
Analyst projections of the future price of Collegium Pharmaceutical stock.

Bulls say / Bears say

JORNAY PM is gaining traction: Q3 revenue rose 24% year on year, prescriptions grew 16%, and the number of prescribers reached a record. That gives Collegium a clear growth engine beyond its legacy pain products. (Collegium Pharmaceutical)
AZSTARYS adds a second ADHD product: it generated $26.5 million in its first full quarter under Collegium, with prescriptions up nearly 2% year on year after declining in 2025. Its patent protection is expected to extend through 2037, giving the company time to build the brand. (Collegium Pharmaceutical, Collegium Pharmaceutical)
Xtampza ER could get a lift from exclusive formulary placement with a large payer covering about 15 million people, starting in January 2027. Prescriptions also rose about 3% sequentially in Q3, despite lower reported revenue. (The Motley Fool)
The pain portfolio is eroding: Q3 revenue fell 18% year on year, with Nucynta down 44% amid generic competition and Xtampza down 9%. This decline is already offsetting growth in ADHD. (Collegium Pharmaceutical)
Belbuca faces a potential generic entrant after a settlement date of 23 January 2027. Teva would still need FDA approval, but a launch could put pressure on a product that generated $57.7 million in Q3 revenue. (The Motley Fool)
Profitability weakened in Q3: adjusted EBITDA fell 9% year on year, GAAP net income declined, and operating expenses rose 44%. Net debt stood at about 2.1 times adjusted EBITDA, leaving less room if product declines persist. (Collegium Pharmaceutical, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

COLL Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

COLL Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.